secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001493152-24-031161
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M
--------------------------------------------------------------------------------

- EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.
- GAAP net loss $11.0M ($0.23/share); non-GAAP adjusted loss $9.7M ($0.20/share).
- Positive clinical data: ENVET-BE study shows 2.4x increased yield; BE-1 study 88% sensitivity, 99% NPV.
- Cash $24.9M after $11.6M Series B-1 preferred stock issuance; held CMS MAC Palmetto GBA MolDX meeting.
- First major #CheckYourFoodTube event with upfront contracted payment; revenue cycle management improving.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224031161/0001493152-24-031161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315224031161/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-031161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer